Methaemoglobin (SpMet^®) is a breakthrough measurement that allows clinicians to noninvasively and immediately detect elevated levels of methaemoglobin in the blood—facilitating earlier diagnosis and treatment for patients with methaemoglobinemia, a dangerous but underdiagnosed and undertreated condition.

• > Methaemoglobinemia is an important clinical condition, more common than generally believed, and is linked to increased morbidity and mortality.¹
• > Many procedures and drugs commonly used in clinical practice—including iNO therapy in neonates—have been documented as contributing to induced methaemoglobinemia.¹
• > Methaemoglobinemia occurs across all care areas and patient populations yet is often unrecognised and misdiagnosed.¹

"Acquired Methemoglobinemia is fairly common and causes morbidity and mortality in both the inpatient and outpatient settings. Acquired methemoglobinemia is often unrecognised and thus untreated."

Dr. Rachel Ash-Bernal
and other researchers at Johns Hopkins Hospital

Technology Platform

Masimo rainbow SET^® is a noninvasive monitoring platform enabling the assessment of multiple blood constituents and physiologic parameters that previously required invasive or complicated procedures, in addition to providing Masimo SET^® Measure-through Motion and Low Perfusion pulse oximetry.

PDF Resources

REFERENCES

• ¹ Ash-Bernal R, Wise R, Wright SM. Acquired Methemoglobinemia. A Retrospective Series of 138 Cases at 2 Teaching Hospitals. Medicine. 2004; 83: 265-272.